From data to drug: the translational impact of RaDaR, the UK national registry of rare kidney diseases.

WHY IT MATTERS

If you have a rare kidney disease, RaDaR's data is helping researchers design better clinical trials and identify which patients might benefit from new treatments — meaning faster access to potential therapies tailored to your specific condition.

The UK created a large database called RaDaR to collect detailed health information from patients with rare kidney diseases. With over 37,000 patients enrolled, this database helps researchers understand these diseases better, find new treatments, and run clinical trials more effectively. By gathering this information in one place, scientists can develop new medicines faster for conditions that affect relatively few people.

From data to drug: the translational impact of RaDaR, the UK national registry of rare kidney diseases. Abstract: Each rare kidney disease affects relatively few individuals, but collectively these disorders place a significant burden on patients, families, healthcare systems and society. Historically, therapeutic development has been limited by diagnostic challenges, small and underpowered trials, and a lack of disease-specific, clinically meaningful endpoints acceptable to regulators. The UK National Registry of Rare Kidney Diseases (RaDaR) was launched in 2010 to address these challenges by capturing high-quality longitudinal data. With over 37 000 participants enrolled across more than 100 UK sites, RaDaR now functions as a nationally integrated research platform supporting epidemiological studies, biomarker and genomic research, clinical trial feasibility and recruitment, patient-reported Authors: Gale Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association MeSH: Humans, Registries, Rare Diseases, Kidney Diseases, United Kingdom, Translational Research, Biomedical